Alzheimer's Blood Tests Cleared; Measles Peaks at 4,400; EU Backs Pancreatic Drug
Two FDA approvals — Alzheimer's blood tests and a home-use thyroid therapy — plus an EU pancreatic cancer ruling, as US measles tops 4,410 cases.
By Dr. Asher Knippel
A week of consequential regulatory decisions brought new diagnostic tools for Alzheimer's disease and a first-of-its-kind home-use therapy for thyroid eye disease, while an EU drug panel recommended a novel pancreatic cancer treatment. Against that backdrop, the United States measles outbreak reached a sobering milestone, and Cyprus quietly advanced one of the region's more ambitious healthcare partnerships.
Wednesday, 15 October: FDA Approves Two Blood Tests for Alzheimer's Disease
The US Food and Drug Administration cleared two blood-based diagnostic tests for Alzheimer's disease in adults presenting with cognitive symptoms — a regulatory milestone that clinicians have anticipated since amyloid-targeting therapies created a practical need for earlier, less invasive confirmation of disease biology.
Blood-based testing marks a meaningful step toward wider access. Traditional Alzheimer's diagnosis relies on cerebrospinal fluid sampling — which requires a lumbar puncture — or PET brain imaging, both of which are costly, specialist-dependent, and unavailable in most community settings. A validated blood test draws from a standard venepuncture, opening the door to primary-care screening across general practice and memory clinics. Experts caution that these tests measure amyloid burden as a biomarker, not dementia severity; a positive result should trigger specialist review and shared decision-making before any treatment is initiated. The approvals are also expected to reshape clinical trial design: researchers are now debating whether blood biomarker status should anchor eligibility criteria rather than PET confirmation alone, which could dramatically expand the pool of eligible participants and accelerate enrolment.
Wednesday, 15 October: Roche Wins FDA Clearance for First At-Home Thyroid Eye Disease Therapy
The FDA granted approval to Roche's Enspryng as the first subcutaneous, self-injectable treatment for thyroid eye disease — a serious autoimmune condition in which inflammation behind the eye causes painful protrusion, double vision, and, in severe cases, permanent vision loss. Previously, the only approved option required intravenous infusion at a medical facility every three weeks. Subcutaneous administration can be performed at home by the patient or a trained caregiver after a brief orientation session.
In the pivotal Phase 3 trial, 52.9 percent of participants in the treatment arm achieved a clinically meaningful reduction in proptosis (eye protrusion), compared with 23.4 percent in the placebo group. The safety profile was consistent with Enspryng's existing approved indication, with no new signals identified. For patients across Cyprus and Greece, where thyroid-related autoimmune conditions carry a modestly elevated prevalence linked to iodine-intake variability in the eastern Mediterranean diet, the home-use format reduces dependence on specialist infusion centres and should ease access in communities outside the main urban hospitals.
Recent: EU Drug Panel Backs Daraxonrasib for Metastatic Pancreatic Cancer
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending European Commission approval of daraxonrasib for adults with previously treated metastatic pancreatic ductal adenocarcinoma harbouring a KRAS G12D mutation — one of the most common and historically undruggable alterations in oncology.
Pancreatic cancer carries among the lowest five-year survival rates of any solid tumour, partly because most patients present at an advanced stage and first-line chemotherapy responses are often short-lived. Daraxonrasib is a direct KRAS G12D inhibitor. Earlier KRAS-targeting drugs focused on the G12C variant found more often in lung cancer; the G12D variant predominates in pancreatic tumours and has proven far harder to block. A European Commission decision typically follows a CHMP positive opinion within two months, which would make daraxonrasib the first approved targeted therapy for KRAS G12D-driven pancreatic cancer in the EU. In the US, the FDA had granted daraxonrasib breakthrough therapy designation earlier in the year for a first-line combination regimen.
Thursday, 16 October: US Measles Surge — 4,410 Cases, Six Deaths in Pennsylvania
The US Centers for Disease Control and Prevention recorded 4,410 measles cases nationwide as of mid-October 2026 — a rise of 330 in a single week and the largest domestic outbreak in decades. Pennsylvania is the epicentre: six deaths linked to measles have been reported in the state since August, though the CDC's public tracker currently acknowledges two of them, describing the remaining four as under review. The agency has deployed an epidemiologist to assist state and local investigators on the ground.
The outbreak follows the removal of childhood vaccination requirements in several US states and declining MMR (measles-mumps-rubella) uptake in certain faith-based and semi-rural communities. Measles is among the most contagious pathogens known: a single unvaccinated person exposed to a case has roughly a 90 percent chance of infection. The EU's ECDC has separately flagged measles spread across European countries this season. Travellers returning from the United States or affected European regions who are not certain of their immune status should confirm two-dose MMR coverage with their clinician or public health service before travel.
Tuesday, 14 October: Cyprus Moves to Close the Innovation-to-Patient Gap in Medicine
An October 14 report from the Cyprus Mail describes a coordinated push to strengthen the island's clinical research infrastructure and shorten the lag between European regulatory approval and reimbursable patient access within GESY, the national health system. Under the current framework, drugs approved by the EMA can take 12 to 24 months to become locally reimbursable — a delay that advocates say is clinically consequential for oncology and rare-disease patients.
The initiative focuses on attracting Phase 2 and Phase 3 clinical trial activity to Cypriot hospitals, which would simultaneously improve data for Mediterranean-specific patient populations and give trial participants access to investigational therapies ahead of broad market entry. The Bank of Cyprus Oncology Centre, which recently launched a PET/CT imaging service to improve cancer staging and treatment monitoring, is positioned as a key anchor site for this strategy.
Thursday, 16 October: Hadassah Medical Centre Limassol Formally Inaugurated
Israel's Hadassah Medical Organisation officially opened its Limassol branch — described as the first Hadassah centre in Europe — formally inaugurating what began seeing patients in July 2026. The centre is affiliated with the Hadassah Medical Centre in Jerusalem, long regarded as one of the region's most advanced academic hospitals.
For patients in Cyprus, the facility offers on-island access to multidisciplinary oncology and complex medicine services that have historically required travel to Nicosia, Athens, or abroad. The opening reflects a broader trend of Israeli and European health organisations establishing clinical footholds in the eastern Mediterranean, with Limassol's position as a regional business hub making it a natural access point.
This article is journalistic reporting compiled from publicly available sources. It does not constitute medical advice and is not a substitute for the guidance of a qualified clinician. Readers should consult their doctor or a registered healthcare professional before making any change to their treatment, medication, or health routine.